MULTIPLE TREATMENT EFFECTS
Control adrenal androgens
Reduce GC doses1-4
CRENESSITY can help you do both by managing androgens differently
CRENESSITY was studied in the largest-ever clinical trial program for a classic CAH treatment. Efficacy in both children and adults was evaluated based on:
- Reduction in androstenedione levels
- Reduction in GC doses
Demonstrated safety Profile
Studied in pediatric and adult patients1,3,4
Most common adverse reactions in children taking CRENESSITY were headache, abdominal pain, fatigue, nasal congestion, and epistaxis. Most common adverse reactions in adults taking CRENESSITY were fatigue, headache, dizziness, arthralgia, back pain, decreased appetite, and myalgia.
- *A total of 3% of children treated with CRENESSITY and no placebo-treated patients discontinued treatment because of adverse reactions of abdominal pain, myalgia, and dizziness. A total of 3% of adults treated with CRENESSITY and no placebo-treated patients discontinued treatment because of adverse reactions of restlessness, apathy, dyspepsia, nausea, and vomiting. One adult discontinued during the randomized phase. Three additional adults and 2 children discontinued after the randomized phase. One additional patient withdrew from CAHtalystTM Pediatric.
ACCESS SIMPLIFIED
Dedicated support for those prescribed CRENESSITY
Personalized support at every step to ensure timely access, with most patients paying $10 or less a month for CRENESSITY*
- *Additional terms and conditions apply.
REFERENCES
- Crenessity. Package insert. Neurocrine Biosciences, Inc.
- Neurocrine Biosciences announces FDA approval of CRENESSITY (crinecerfont), a first-in-class treatment for children and adults with classic congenital adrenal hyperplasia. News release. Neurocrine Biosciences. December 13, 2024. Accessed December 13, 2024. https://neurocrine.gcs-web.com/news-releases/news-release-details/neurocrine-biosciences-announces-fda-approval-crenessitytm
- Sarafogolu K, Kim MS, Lodish M, et al. Phase 3 trial of crinecerfont in pediatric congenital adrenal hyperplasia. N Engl J Med. 2024;391(6):493-503. doi:10.1056/NEFMoa2404655
- Auchus RJ, Hamidi O, Pivonello R, et al. Phase 3 trial of crinecerfont in adult congenital adrenal hyperplasia. N Engl J Med. 2024;391(6):504-514. doi:10.1056/NEJMoa2404656